ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular"

  • Abstract Number: 0900 • ACR Convergence 2022

    Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients

    Dimitrios Pappas1, Jon Giles2, George Reed3, Kevin Kane4, Jeffrey Curtis5 and Joel Kremer6, 1CorEvitas, LLC, Waltham, MA, 2Columbia University, New York, NY, 3The Corrona Research Foundation and University of Massachusetts, Albany, NY, 4University of Massachusetts, Worcester, MA, 5University of Alabama at Birmingham, Hoover, AL, 6The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: Cardiovascular (CV) risk in RA is increased due to interaction between traditional risk factors and systemic inflammation. The purpose of this analysis was to…
  • Abstract Number: 1216 • ACR Convergence 2022

    Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India

    Salil Ganu, C. B. Mithun and Jyothi Visalakshy, Amrita Institute of Medical Sciences, Kochi, India

    Background/Purpose: Fibromyalgia is known to be associated with cardiovascular events and mortality. We aimed to compare the prevalence of subclinical atherosclerosis (SAT), a surrogate marker…
  • Abstract Number: 1532 • ACR Convergence 2022

    The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging

    sanya Chhikara1, Adinan Kanda2, mohamed Ismail2, Fredrick Ogugua2, Rejowana Rouf2, khaled Ismail2, Parag Bawaskar2, Jerry Molitor2 and Chetan Shenoy2, 1University of Minnesota, New York, NY, 2University of Minnesota, Minneapolis, MN

    Background/Purpose: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to coronary artery disease, pulmonary, or renal disease. The prevalence of the primary…
  • Abstract Number: 1815 • ACR Convergence 2022

    Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease

    Gary Ho1, Michael Toprover2, Daria Crittenden3, binita Shah4 and Michael Pillinger5, 1New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, 2Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, 3CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, 4New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, 5NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
  • Abstract Number: 2215 • ACR Convergence 2022

    Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis

    Daniel Solomon1, Jon Giles2, Katherine Liao1, Paul Ridker1, Pamela Rist1, Robert Glynn1, Rachel Broderick3, Fengxin Lu1, Meredith Murray1, Kathleen Vanni1, Leah Santacroce1, Shady Abohashem4, Philip Robson5, Zahi Fayad6, Venkatesh Mani5, Ahmed Tawakol4 and Joan Bathon7, 1Brigham and Women's Hospital, Boston, MA, 2Columbia University, New York, NY, 3Columbia University, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Icahn School of Medicine at Mount Sinai, New York, NY, 6Mount Sinai, New York, NY, 7Columbia University Medical Center, New York, NY

    Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…
  • Abstract Number: 0171 • ACR Convergence 2022

    Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?

    Matilde Bandeira1, Eduardo Dourado1, Ana Teresa Melo1, Patricia Martins2, Vanessa Fraga3, José Luís Ferraro4, André Saraiva5, Marlene Sousa6, Hugo Parente7, Catarina Soares8, Ana Margarida Correia9, Diogo Esperança Almeida9, Sara Paiva Dinis10, Ana Pinto11, Filipe Pinheiro12, Maria Rato12, Tiago Beirão13, Beatriz Samões13, Bernardo Santos14, Carolina Mazeda15, Ana Teodósio Chícharo16, Margarida Faria17, Agna Neto17, Helena Lourenço18, Luísa Brites19, Marília Rodrigues19, Joana Silva-Dinis20, João Madruga-Dias21, Filipe Araújo22, Nádia Martins23, Maura Couto23, Ana Valido24, Maria José Santos25, Sofia Barreira1, João Eurico Fonseca1 and Raquel Campanilho-Marques1, 1Serviço de Reumatologia, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa (CAML), Lisboa, Portugal; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, CAML, Lisboa, Portugal, 2Rheumatology department, Centro Hospitalar e Universitário de Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, 3Serviço de Reumatologia, Hospital Beatriz Ângelo, Almada, Portugal, 4Serviço de Reumatologia, Hospital Beatriz Ângelo, Loures, Portugal, 5Rheumatology department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 6Serviço de Reumatologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, 7Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, 8Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, 9Serviço de Reumatologia, Hospital de Braga, Braga, Portugal, Braga, Portugal, 10Rheumatology department, Unidade Local de Saúde da Guarda - Hospital Sousa Martins, Guarda, Portugal, 11Local Health Unit of Guarda, Barcelos, Portugal, 12Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 13Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, 14Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, 15Centro Hospitalar Baixo Vouga, Ovar, Portugal, 16Serviço de Reumatologia, Centro Hospitalar Universitário do Algarve, Faro, Portugal, 17Serviço de Reumatologia, Hospital Nélio Mendonça, Serviços de Saúde da Região Autónoma da Madeira, Funchal, Portugal, 18Serviço de Reumatologia, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, 19Serviço de Reumatologia, Centro Hospitalar de Leiria, Leiria, Portugal, Leiria, Portugal, 20Serviço de Reumatologia, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal, 21Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, 22Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, 23Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, 24Serviço de Reumatologia, Unidade Local de Saúde do Litoral Alentejano, Santiago do Cacém, Portugal, 25Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare disorders that can affect the heart. It is unclear which patients are at higher risk.…
  • Abstract Number: 0477 • ACR Convergence 2022

    Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?

    Hubert De Boysson1, Anael DUMONT2, Samuel DESHAYES2, Alexandre Nguyen2 and Achille Aouba1, 1Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 2Caen University Hospital, Caen, France

    Background/Purpose: We analyzed whether the use of beta-blockers in addition to conventional care in patients with Giant cell arteritis (GCA) and large vessel vasculitis (LVV)…
  • Abstract Number: 0903 • ACR Convergence 2022

    Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis

    Emil Rydell1, Lennart Jacobsson2 and Carl Turesson3, 1Lund University, Malmö, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A,…
  • Abstract Number: 1240 • ACR Convergence 2022

    A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy for the Diagnosis of Cardiac Sarcoidosis

    Omar Abialmouna1, Mohamad Kalot2, Mohamad Hamade3, Ronak Bahuva2, Ariba Hasmi2, Aamir Ahmed2, Zachary Brumberger2, Jordan Troy2, Ali Choaib4, Ronak Bharucha2, Ross Moyer2, Karin Provost2, Brian Page2 and Umesh Sharma2, 1University at Buffalo, North Tonawanda, NY, 2University at Buffalo, Buffalo, NY, 3University of Miami, Miami, FL, 4Lebanese American University, Beirut, Lebanon

    Background/Purpose: Autopsy reports for patients with sarcoidosis have suggested that up to 25% have cardiac involvement, mostly undiagnosed. Given the limited diagnostic accuracy of endomyocardial…
  • Abstract Number: 1535 • ACR Convergence 2022

    Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis

    Jessica Fairley1, Laura Ross2, Alannah Quinlivan3, Dylan Hansen4, Elizabeth Paratz5, Wendy Stevens4, Peter M Kistler6, Andre La Gerche7 and Mandana Nikpour8, 1The University of Melbourne, Melbourne, Australia, 2The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, 3St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, 4St Vincent's Hospital Melbourne, Melbourne, Australia, 5The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, 6The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, 7The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, 8The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
  • Abstract Number: 1816 • ACR Convergence 2022

    Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study

    Ira Khanna, Venkatesh Mani, Renata Pyzik, Audrey Kaufman, Wei Wei Chi, Emilia Bagiella, Philip Robson and Yousaf Ali, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Gout is the most common inflammatory arthritis, caused by hyperuricemia and subsequent deposition of aggregated monosodium urate (MSU) crystals in both articular and extra-articular…
  • Abstract Number: 2217 • ACR Convergence 2022

    Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity

    Amir Razmjou1, Jennifer Wang1, Ani Shahbazian1, Jeffrey Curtis2, Dimitrios Pappas3, Joel Kremer4 and Christina Charles-Schoeman5, 1UCLA Medical Center, Los Angeles, CA, 2University of Alabama at Birmingham, Hoover, AL, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation, Delray Beach, FL, 5Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

    Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
  • Abstract Number: 0244 • ACR Convergence 2022

    Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab

    Yicong Li1, Chun Wu2, Michael Maldonado2, Peter Schafer2, S. Louis Bridges, Jr.3, William Rigby4, Vivian Bykerk3, Jane Buckner5 and Jinqi Liu2, 1Parexel International, Durham, NC, 2Bristol Myers Squibb, Princeton, NJ, 3Hospital for Special Surgery, New York, NY, 4Dartmouth Hitchcock Medical Center, Lebanon, PA, 5Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: Effective RA therapies should not only improve joint signs and symptoms, but also mitigate additional disease-related consequences, such as the increased risk of cardiovascular…
  • Abstract Number: 0539 • ACR Convergence 2022

    Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use

    Anna Broder1, Wenzhu B. Mowrey2, Kazuki Yoshida3 and Karen Costenbader3, 1Hackensack University Medical Center, Hackensack, NJ, 2Albert Einstein College of Medicine, Bronx, NY, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
  • Abstract Number: 0908 • ACR Convergence 2022

    The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis

    Arkady Manning-Bennett1, Ashley Hopkins2, Michael Sorich2, Susanna Proudman3, David Foster1, Ahmad Abuhelwa2 and Michael Wiese1, 1University of South Australia, Adelaide, Australia, 2Flinders University, Adelaide, Australia, 3Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that is characterised by inflammation in the synovium of diarthrodial joints and low-level inflammation in multiple…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology